WHO recommends two new drugs to treat COVID-19
The extent to which these medicines, Baricitinib and Sotrovimab, will save lives depends on how widely available and affordable…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Ruxolitinib
Topical JAK inhibitors becoming a major force in atopic dermatitis space: GlobalData
An increasing number of JAK agents are filling the early and late-stage pipeline. Of the 98 pipeline agents, eight are JAKs – with…
Ruxolitinib (Jakafi) does not prevent complications due to COVID-19 associated cytokine storm: Study
There was no reduction in the proportion of patients receiving ruxolitinib plus SoC who experienced severe complications including…